At What Price Is Canopy Growth (TSX:WEED) Stock Worth Buying?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is the king of the cannabis castle, but is it really worth the price it currently trades for?

| More on:
edit Jars of marijuana

Image source: Getty Images

Lately, it’s been quiet on the Canopy Growth Corp (TSX:WEED)(NYSE:CGC) front. The marijuana stock that previously had a beta coefficient higher than 4, has been stable around $60 for weeks. So far this year, the stock has risen about 54%, but the majority of those gains were locked in by January 30. Since then, the stock has been trading in a $6 price range and holding steady.

The fact that Canopy is now fairly flat may indicate that speculators have lost interest in the stock, and that most people holding it are in for the long term. If that’s the case, the usual price and value calculations now apply to Canopy–which in the past was a pure momentum play.

To gauge what price Canopy is worth today, we need to look at how the company is doing relative to its fundamentals.

Valuation

Canopy has historically been a pretty expensive stock, trading at up to 200 times sales. For the recent 12-month period, Canopy traded at 136 times sales, which is still very high. For the same period, earnings were negative. It is possible to calculate a “P/E ratio” for the most recent quarter: using the basic EPS figure ($0.22), it’s about 272. However, P/E ratios are usually calculated with 12-month data or forward projections, so this isn’t a conventional approach.

The big takeaway is that Canopy is very expensive relative to sales and earnings. However, this may not make the stock overvalued if we take growth into consideration as well.

Growth

As you might know, a high P/E ratio does not necessarily mean a stock is overvalued. If growth is high, a P/E ratio may be high (and justified) as well. A great example of this would be Amazon.com, whose P/E ratio has historically hovered over 100 without harming the stock’s return at all.

Currently, Canopy is growing even faster than Amazon at its peak, with sales up 280% and profits up 4000% year over year. That kind of growth can make a pretty high P/E ratio look insignificant in comparison. At the same time, Canopy’s recent positive earnings were because of fair value changes rather than operations; the company’s operating income was still $-78 million. This calls into question whether we’re really seeing an increasingly profitable company here, or one that got lucky one quarter.

Analyst targets

A final factor to take into account when evaluating a fair stock price is analyst targets. The world’s largest banks and mutual funds rely on analyst ratings to guide their investing decisions, so these figures are considered reliable.

According to the Wall Street Journal, the median analyst target price for Canopy is $72, while the highest is $100 and the lowest is $15. Going off the median, Canopy still has plenty of room to grow before it hits a price analysts consider fair. In light of that, now seems like a good time to buy Canopy shares. But it’s important to remember that this is a very volatile stock that has often behaved in ways that analysts didn’t expect.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Andrew Button has no position in any of the stocks mentioned. David Gardner owns shares of Amazon. The Motley Fool owns shares of Amazon.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »